Liraglutide (Daily GLP-1)

Liraglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist administered as a once-daily subcutaneous injection. Unlike weekly GLP-1 agents, liraglutide's shorter half-life means it is dosed daily, which some patients and providers prefer for its more granular dose-control flexibility. FormBlends offers liraglutide as a compounded formulation in a 10 mg/mL multi-dose vial (5 mL), prepared by a licensed 503A compounding pharmacy.

Liraglutide exerts its effects by activating GLP-1 receptors in the pancreas, gut, and central nervous system. Pancreatic engagement promotes glucose-dependent insulin release and suppresses glucagon secretion. In the gastrointestinal tract, it slows gastric emptying, contributing to a prolonged sense of fullness after meals. In the brain, GLP-1 receptor signaling in the hypothalamus and brainstem is associated with reduced appetite and decreased food intake, which may support caloric reduction when paired with dietary modification.

Treatment typically begins at a lower dose and is gradually increased over several weeks in accordance with a provider-established titration schedule. This approach is intended to allow the body to adapt to GLP-1 receptor activation and to minimize the incidence of gastrointestinal side effects. Your provider will determine the appropriate starting dose, escalation pace, and target maintenance dose based on your individual clinical profile and tolerability.

This formulation may be a fit for adults with a BMI indicating overweight or obesity, particularly those who prefer a daily injectable dosing schedule or for whom a daily format is clinically appropriate. Liraglutide is not appropriate for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Use alongside a reduced-calorie diet and increased physical activity is a key component of the treatment approach.

Common side effects associated with GLP-1 receptor agonists include nausea, vomiting, diarrhea, and constipation, which are most likely to occur during dose escalation and generally diminish over time. Pancreatitis has been reported with GLP-1 agents; patients with a history of pancreatitis should discuss this with their provider. Regular monitoring and follow-up with your care team are important throughout treatment. This is a compounded medication and is not FDA-approved in this format.